Bone Biologics Co. (NASDAQ:BBLG) Short Interest Up 21.0% in November

Bone Biologics Co. (NASDAQ:BBLG) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 70,400 shares, an increase of 21.0% from the November 15th total of 58,200 shares. Based on an average daily volume of 3,010,000 shares, the short-interest ratio is currently 0.0 days. Currently, 13.2% of the shares of the stock are sold short.

Bone Biologics Stock Performance

Shares of NASDAQ:BBLG opened at $1.12 on Monday. Bone Biologics has a 1-year low of $0.80 and a 1-year high of $10.56. The company has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.50.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.